Abstract
Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treatment resulted in robust upregulation ofSRCactivity, as measured by the phosphorylation of theSRCsubstrate paxillin. Knockdown ofSRCalone with siRNAeffectively sensitized ceritinib resistance inALK‐positive cells. Furthermore,SRCinhibition byAZD0530 was effective inALK‐resistant cancer cells. Thus,ALKinhibition by ceritinib may lead to upregulation ofSRCsignaling, andAZD0530 could serve as a potential drug in the clinic to treatALK‐resistant lung cancer patients.

This publication has 20 references indexed in Scilit: